CSIMarket Company Name, Ticker, Competitors, else..
 
Athira Pharma Inc   (NASDAQ: ATHA)
Other Ticker:  
 
 
Price: $0.5304 $0.00 -0.094%
Day's High: $0.55 Week Perf: -0.13 %
Day's Low: $ 0.52 30 Day Perf: -8.14 %
Volume (M): 45 52 Wk High: $ 4.30
Volume (M$): $ 24 52 Wk Avg: $2.02
Open: $0.53 52 Wk Low: $0.41



 Market Capitalization (Millions $) 20
 Shares Outstanding (Millions) 39
 Employees 86
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -115
 Cash Flow (TTM) (Millions $) -36
 Capital Exp. (TTM) (Millions $) 0

Athira Pharma Inc
Athira Pharma Inc is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, particularly Alzheimer's disease. The company's approach involves targeting the regeneration and restoration of brain cells and neural connections to reverse the progression and symptoms of these diseases. Athira Pharma is conducting clinical trials and using a proprietary technology platform to identify and develop potential drug candidates. The ultimate goal of Athira Pharma is to improve the lives of patients by finding effective treatments for neurodegenerative diseases.


   Company Address: 18706 North Creek Parkway Bothell 98011 WA
   Company Phone Number: 620-8501   Stock Exchange / Ticker: NASDAQ ATHA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        0.71% 
BIIB   -6.41%    
CHRS   -5.44%    
EXEL        2.55% 
GILD        2.11% 
HALO        1.22% 
• View Complete Report
   



Clinical Study

Athira Pharma Unveils Preclinical Data on Neuroprotective Effects of ATH-1105 for ALS at International Symposium,

Published Fri, Dec 6 2024 10:30 PM UTC

Preclinical Data Demonstrating Neuroprotective Effects of ATH-1105 in ALS Models Presented by Athira Pharma BOTHELL, Wash., Dec. 6, 2024 Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of small molecules aimed at restoring neuronal health and mitigating neurodegeneration, has recently unveiled promising preclini...
Clinical Study

for This Athira Pharmas Fosgonimeton Stumbles in Phase 2/3 Alzheimers Trial, But Commitment to Neurologic...

Published Tue, Sep 3 2024 8:01 PM UTC

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer?s Disease LIFT-AD Trial Did Not Meet Primary Endpoint of GST and Key Secondary Endpoints of Cognition (ADAS-Cog11) and Function (ADCS-ADL23)In a significant update for the medical and scientific community, Athira Pharma has announced the topline resul...
Clinical Study

ne

Published Wed, Jul 31 2024 12:05 PM UTC

Athira Pharma Unveils Groundbreaking Preclinical Data on Fosgonimeton at AAIC 2024, Elevating Hope for Alzheimer s Treatment and Announcing Progress in ALS Drug Candidate Development In a pivotal moment for the ongoing battle against neurodegenerative diseases, Athira Pharma took center stage at the Alzheimer?s Association International Conference (AAIC) 2024, where they pre...
Stocks on the Move

for the article Athira Pharma (ATHA) Completes Groundbreaking Alzheimers Study, Sends Stock Soaring

Published Wed, Jul 10 2024 7:35 PM UTC

Athira Pharma Inc. (ATHA) witnessed a significant surge in its stock price following the completion of dosing for the last patient in its phase II/III LIFT-AD study. The study focused on evaluating the efficacy of fosgonimeton in treating individuals with mild-to-moderate Alzheimer s disease. This milestone achievement has instilled hope among investors, resulting in a notab...
Clinical Study

Promising Findings on Fosgonimeton Highlight its Potential in Preserving Neuronal Health in Neurodegenerative Diseases

Published Wed, Jun 12 2024 11:00 AM UTC

In a recent revelation, Athira Pharma s webinar shed light on the potential of Fosgonimeton in protecting and preserving neuronal health in patients suffering from mild-to-moderate Alzheimer s disease. This breakthrough showcases the emerging role of Fosgonimeton as a therapeutic agent in the treatment of various neurodegenerative conditions.Athira Pharma, a leading biotech ...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com